327 related articles for article (PubMed ID: 24737877)
1. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
American Society of Clinical Oncology
J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
[No Abstract] [Full Text] [Related]
2. The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2004 Feb; 350(6):608-13. PubMed ID: 14762190
[No Abstract] [Full Text] [Related]
3. PhRMA sues on 340B orphans.
Lee J
Mod Healthc; 2013 Oct; 43(40):17. PubMed ID: 24340726
[No Abstract] [Full Text] [Related]
4. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
[TBL] [Abstract][Full Text] [Related]
5. The Reach of the 340B Drug Pricing Program.
Albrecht J; Mudahar S
JAMA Dermatol; 2015 Sep; 151(9):923-4. PubMed ID: 25993384
[No Abstract] [Full Text] [Related]
6. Rx: higher prices.
Kosterlitz J
Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
[TBL] [Abstract][Full Text] [Related]
7. Medicare and drug pricing.
Iglehart JK
N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
[No Abstract] [Full Text] [Related]
8. CMS retreats on Part D rule intended to reduce drug costs and improve access.
Dickson V
Mod Healthc; 2014 Mar; 44(11):10. PubMed ID: 24830094
[No Abstract] [Full Text] [Related]
9. Tips for preparing for a 340B integrity audit.
Wood W; Jorgenson J; Kelly W
Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
[TBL] [Abstract][Full Text] [Related]
10. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
Werling K; Abraham S; Strelec J
Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
[No Abstract] [Full Text] [Related]
11. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
Sarpatwari A; Avorn J; Kesselheim AS
JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
[No Abstract] [Full Text] [Related]
12. Opinion: price controls on prescription drugs.
Franks B
N J Med; 2004 Apr; 101(4):56, 55. PubMed ID: 15103791
[No Abstract] [Full Text] [Related]
13. Novel approaches to delivering value in oncology drugs.
Miller S
Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
[No Abstract] [Full Text] [Related]
14. Prescription-drug prices.
Frank RG
N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
[No Abstract] [Full Text] [Related]
15. Creating a medical home through the 340B Drug Pricing Program.
Genao I; Hendrickson K; Diers D; Browne R; Rawlings JE
Conn Med; 2010; 74(10):615-20. PubMed ID: 21189719
[TBL] [Abstract][Full Text] [Related]
16. States sue generic drug makers for alleged price fixing.
McCarthy M
BMJ; 2016 Dec; 355():i6764. PubMed ID: 27993771
[No Abstract] [Full Text] [Related]
17. American pharmaceutical prices.
Alagona P
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
[No Abstract] [Full Text] [Related]
18. Can price and regulatory controls replace free market competition in the drug industry?
Buc NL; Levitt GM
Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
[No Abstract] [Full Text] [Related]
19. Keynote comment: Cancer drug pricing in the USA.
Johnson DH
Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
[No Abstract] [Full Text] [Related]
20. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
